• Cryptocurrencies
  • Voorspellingsmarkten
  • Nieuws
  • Agentisch Handelen
  • Artikelen
  • Competities

Zoeken Cryptocurrencies

Trends Cryptocurrencies

CoinRithm

Bedrijf

Rechtspersoon
Bees-x Limited
Bedrijfsnummer
13308136
Opgericht in
England and Wales
Statutaire zetel
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm is een informatie- en onderzoeksdienst van Bees-x Limited. Het is niet door de Financial Conduct Authority (FCA) gemachtigd om gereguleerde activiteiten uit te voeren, en niets op deze site vormt financieel advies.

Ontdekken

CryptocurrenciesVoorspellingsmarktenNieuwsArtikelenAgent ArenaCompetities

Functies

DashboardNephandelAgentisch HandelenPortefeuilleVolglijstInstellingen

Bedrijf

Over OnsMethodologieGebruiks- voorwaardenPrivacybeleidCookiebeleidVrijwaring

Ondersteuning

KlantenserviceFAQOntwikkelaarskitMCP-documentatie

Sociale Media

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Rechten voorbehouden.
Verkrijgbaar via Google PlayDownloaden in de App Store
  • Home
  • MarktenVoorspellingsmarkten
  • Nieuws
  • Dashboard
  1. Voorspellingsmarkten
  2. Health & Medicine
  3. FDA approves Retatrutide this year?
FDA approves Retatrutide this year?

FDA approves Retatrutide this year?

1.0% (24u)Health & MedicineOne-Off6mnd
PolymarketPolymarketBeschikbaarheid controlerenGeen KYC2% kosten
Huidige impliciete kans
Ja
Ja 12%-0.0%
Marktkwaliteit

52 / 100

Gemiddelde kwaliteit
24u volume

€ 238,8

Liquiditeit

€ 2,4K

Gemiddelde liquiditeit
Bied / Laat

11.0% / 12.0%

Spread

9.1%

Brede spread
7d wijziging

-4.5%

Marktdata

Bijgewerkt 5 minuten geleden

12 jan 26, 23:0931 dec 26, 0:00

Trends

Uitkomst24uKans

Gekozen uitkomst

Yes12%

KalshiOok beschikbaar op Kalshi

Will the FDA approve retatrutide?

Will the FDA approve retatrutide?

11.0%6mnd
Before Jan 1, 2027
Before Jan 1, 2027
-11.0%17%
Before Jan 1, 2028
Before Jan 1, 2028
-7.0%85%
Before Jul 1, 2028
Before Jul 1, 2028
-7.0%87%

+2 extra uitkomsten

28 • Lage kwaliteitBrede spreadLage liquiditeitDunne markt
Totaal volume€ 102
24u volume€ 5,1
KalshiKALSHI

Regels

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.

Polymarket
  • This market will resolve to "Yes" if the U.S.
  • Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET.
  • Otherwise, this market will resolve to "No."
  • An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
  • The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Vergelijkingsgegevens zijn alleen informatief. Prijzen en liquiditeit kunnen variëren.

Gerelateerde Markten

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

€ 145,3K
Ja: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

€ 16,6K
Ja: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

€ 8,7K
Ja: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

€ 1,3K
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

€ 462,5
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS

Actief in deze onderwerpen

BitcoinBTC$62,978.79+2.53%EthereumETH$1,661.11+1.78%SolanaSOL$65.42+1.74%DogecoinDOGE$0.0851+1.56%XRPXRP$1.12+0.44%BNBBNB$597.15+1.83%

Gerelateerd Nieuws

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Regels

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.

Polymarket
  • This market will resolve to "Yes" if the U.S.
  • Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET.
  • Otherwise, this market will resolve to "No."
  • An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
  • The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs